Identifying candidate genes involved in brain tumor formation

Upsala Journal of Medical Sciences

Volumn 113, Issue 1, 2008, Pages 1-38

  Swartling, Fredrik Johansson ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PLATELET DERIVED GROWTH FACTOR;

ANIMAL; BRAIN TUMOR; GENETICS; GLIOMA; MOUSE; NEWBORN; REVIEW;

ANIMALS; ANIMALS, NEWBORN; BRAIN NEOPLASMS; GLIOMA; MICE; PLATELET-DERIVED GROWTH FACTOR;

EID: 48949096144     PISSN: 03009734     EISSN: None     Source Type: Journal    
DOI: 10.3109/2000-1967-215     Document Type: Review

References (240)

1. Kleihues, P., Louis, D.N., Scheithauer, B.W., Rorke, L.B., Reifenberger, G., Burger, P.C., and Cavenee, W.K. 2002. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61:215-225; discussion 226-219.
2. 2007. WHO Classification of Tumours of the Central Nervous System. Lyon: IARC.
3. Legler, J.M., Ries, L.A., Smith, M.A., Warren, J.L., Heineman, E.F., Kaplan, R.S., and Linet, M.S. 1999. Cancer surveillance series [corrected]: brain and other central nervous system cancers: recent trends in incidence and mortality. J Natl Cancer Inst 91:1382-1390.
4. Cavenee, W.K., Weller, M., Furnari, F.B., Berens, M.E., Nagane, M., Plate, K.H., Huang, H.-J.S., Israel, M.A., Newcomb, E.W., Noble, M.D., et al. 2000. Diffusely infiltrating astrocytomas. In World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Nervous System. Lyon: International Agency for Research on Cancer Press. pp.10-21 pp.
5. Behin, A., Hoang-Xuan, K., Carpentier, A.F., and Delattre, J.Y. 2003. Primary brain tumours in adults. Lancet 361:323-331.
6. Coons, S.W., Johnson, P.C., Scheithauer, B.W., Yates, A.J., and Pearl, D.K. 1997. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 79:1381-1393.
7. Holland, E.C. 2001. Gliomagenesis: genetic alterations and mouse models. Nat Rev Genet 2:120-129.
8. Merlo, A. 2003. Genes and pathways driving glioblastomas in humans and murine disease models. Neurosurg Rev 26:145-158.
9. Rich, J.N., and Bigner, D.D. 2004. Development of novel targeted therapies in the treatment of malignant glioma. Nat Rev Drug Discov 3:430-446.
10. Maher, E.A., Furnari, F.B., Bachoo, R.M., Rowitch, D.H., Louis, D.N., Cavenee, W.K., and DePinho, R.A. 2001. Malignant glioma: genetics and biology of a grave matter. Genes Dev 15:1311-1333.
11. Hanahan, D., and Weinberg, R.A. 2000. The hallmarks of cancer. Cell 100:57-70.
12. Gammeltoft, S., Ballotti, R., Kowalski, A., Westermark, B., and Van Obberghen, E. 1988. Expression of two types of receptor for insulin-like growth factors in human malignant glioma. Cancer Res 48:1233-1237.
13. Takahashi, J.A., Fukumoto, M., Igarashi, K., Oda, Y., Kikuchi, H., and Hatanaka, M. 1992. Correlation of basic fibroblast growth factor expression levels with the degree of malignancy and vascularity in human gliomas. J Neurosurg 76:792-798.
14. Weis, J., Schonrock, L.M., Zuchner, S.L., Lie, D.C., Sure, U., Schul, C., Stogbauer, F., Ringelstein, E.B., and Halfter, H. 1999. CNTF and its receptor subunits in human gliomas. J Neurooncol 44:243-253.
15. Rosen, E.M., Laterra, J., Joseph, A., Jin, L., Fuchs, A., Way, D., Witte, M., Weinand, M., and Goldberg, I.D. 1996. Scatter factor expression and regulation in human glial tumors. Int J Cancer 67:248-255.
16. Plate, K.H., Breier, G., Weich, H.A., and Risau, W. 1992. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359:845-848.
17. Constam, D.B., Philipp, J., Malipiero, U.V., ten Dijke, P., Schachner, M., and Fontana, A. 1992. Differential expression of transforming growth factor-beta 1, -beta 2, and -beta 3 by glioblastoma cells, astrocytes, and microglia. J Immunol 148:1404-1410.
18. Kjellman, C., Olofsson, S.P., Hansson, O., Von Schantz, T., Lindvall, M., Nilsson, I., Salford, L.G., Sjogren, H.O., and Widegren, B. 2000. Expression of TGF-beta isoforms, TGF-beta receptors, and SMAD molecules at different stages of human glioma. Int J Cancer 89:251-258.
19. Libermann, T.A., Nusbaum, H.R., Razon, N., Kris, R., Lax, I., Soreq, H., Whittle, N., Waterfield, M.D., Ullrich, A., and Schlessinger, J. 1985. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 313:144-147.
20. Humphrey, P.A., Wong, A.J., Vogelstein, B., Friedman, H.S., Werner, M.H., Bigner, D.D., and Bigner, S.H. 1988. Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. Cancer Res 48:2231-2238.
21. Ekstrand, A.J., Longo, N., Hamid, M.L., Olson, J.J., Liu, L., Collins, V.P., and James, C.D. 1994. Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification. Oncogene 9:2313-2320.
22. Frederick, L., Wang, X.Y., Eley, G., and James, C.D. 2000. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 60:1383-1387.
23. Ekstrand, A.J., James, C.D., Cavenee, W.K., Seliger, B., Pettersson, R.F., and Collins, V.P. 1991. Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 51:2164-2172.
24. Stommel, J.M., Kimmelman, A.C., Ying, H., Nabioullin, R., Ponugoti, A.H., Wiedemeyer, R., Stegh, A.H., Bradner, J.E., Ligon, K.L., Brennan, C., et al. 2007. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318:287-290.
25. Kohler, N., and Lipton, A. 1974. Platelets as a source of fibroblast growth-promoting activity. Exp Cell Res 87:297-301.
26. Ross, R., Glomset, J., Kariya, B., and Harker, L. 1974. A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro. Proc Natl Acad Sci U S A 71:1207-1210.
27. Westermark, B., and Wasteson, A. 1976. A platelet factor stimulating human normal glial cells. Exp Cell Res 98:170-174.
28. Erlandsson, A., Brannvall, K., Gustafsdottir, S., Westermark, B., and Forsberg-Nilsson, K. 2006. Autocrine/Paracrine platelet-derived growth factor regulates proliferation of neural progenitor cells. Cancer Res 66:8042-8048.
29. Jackson, E.L., Garcia-Verdugo, J.M., Gil-Perotin, S., Roy, M., Quinones-Hinojosa, A., Vanden-Berg, S., and Alvarez-Buylla, A. 2006. PDGFR alpha-positive B cells are neural stem cells in the adult SVZ that form glioma-like growths in response to increased PDGF signaling. Neuron 51:187-199.
30. Heldin, C.H., and Westermark, B. 1999. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79:1283-1316.
31. Heldin, C.H., Eriksson, U., and Ostman, A. 2002. New members of the platelet-derived growth factor family of mitogens. Arch Biochem Biophys 398:284-290.
32. Heldin, C.H., and Westermark, B. 1990. Platelet-derived growth factor: mechanism of action and possible in vivo function. Cell Regul 1:555-566.
33. Hermanson, M., Funa, K., Hartman, M., Claesson-Welsh, L., Heldin, C.H., Westermark, B., and Nister, M. 1992. Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res 52:3213-3219.
34. Claesson-Welsh, L. 1994. Platelet-derived growth factor receptor signals. J Biol Chem 269:32023-32026.
35. Nister, M., Libermann, T.A., Betsholtz, C., Pettersson, M., Claesson-Welsh, L., Heldin, C.H., Schlessinger, J., and Westermark, B. 1988. Expression of messenger RNAs for platelet-derived growth factor and transforming growth factor-alpha and their receptors in human malignant glioma cell lines. Cancer Res 48:3910-3918.
36. Fujimoto, M., Weaker, F.J., Herbert, D.C., Sharp, Z.D., Sheridan, P.J., and Story, J.L. 1988. Expression of three viral oncogenes (v-sis, v-myc, v-fos) in primary human brain tumors of neuroectodermal origin. Neurology 38:289-293.
37. Lokker, N.A., Sullivan, C.M., Hollenbach, S.J., Israel, M.A., and Giese, N.A. 2002. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res 62:3729-3735.
38. Doolittle, R.F., Hunkapiller, M.W., Hood, L.E., Devare, S.G., Robbins, K.C., Aaronson, S.A., and Antoniades, H.N. 1983. Simian sarcoma virus onc gene, v-sis, is derived from the gene (or genes) encoding a platelet-derived growth factor. Science 221:275-277.
39. Waterfield, M.D., Scrace, G.T., Whittle, N., Stroobant, P., Johnsson, A., Wasteson, A., Westermark, B., Heldin, C.H., Huang, J.S., and Deuel, T.F. 1983. Platelet-derived growth factor is structurally related to the putative transforming protein p28sis of simian sarcoma virus. Nature 304:35-39.
40. Deinhardt, F. 1980. Biology of primate retroviruses. In Viral Oncology: Raven Press: New York.
41. Ortega, S., Malumbres, M., and Barbacid, M. 2002. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 1602:73-87.
42. Ichimura, K., Schmidt, E.E., Goike, H.M., and Collins, V.P. 1996. Human glioblastomas with no alterations of the CDKN2A (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. Oncogene 13:1065-1072.
43. Reifenberger, G., Reifenberger, J., Ichimura, K., Meltzer, P.S., and Collins, V.P. 1994. Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2. Cancer Res 54:4299-4303.
44. Finlay, C.A., Hinds, P.W., and Levine, A.J. 1989. The p53 proto-oncogene can act as a suppressor of transformation. Cell 57:1083-1093.
45. Louis, D.N. 1994. The p53 gene and protein in human brain tumors. J Neuropathol Exp Neurol 53:11-21.
46. Burgart, L.J., Robinson, R.A., Haddad, S.F., and Moore, S.A. 1991. Oncogene abnormalities in astrocytomas: EGF-R gene alone appears to be more frequently amplified and rearranged compared with other protooncogenes. Mod Pathol 4:183-186.
47. Xu, G.F., O'Connell, P., Viskochil, D., Cawthon, R., Robertson, M., Culver, M., Dunn, D., Stevens, J., Gesteland, R., White, R., et al. 1990. The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell 62:599-608.
48. Martin, G.A., Viskochil, D., Bollag, G., McCabe, P.C., Crosier, W.J., Haubruck, H., Conroy, L., Clark, R., O'Connell, P., Cawthon, R.M., et al. 1990. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell 63:843-849.
49. Samuels, Y., Diaz, L.A., Jr., Schmidt-Kittler, O., Cummins, J.M., Delong, L., Cheong, I., Rago, C., Huso, D.L., Lengauer, C., Kinzler, K.W., et al. 2005. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7:561-573.
50. Broderick, D.K., Di, C., Parrett, T.J., Samuels, Y.R., Cummins, J.M., McLendon, R.E., Fults, D.W., Velculescu, V.E., Bigner, D.D., and Yan, H. 2004. Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res 64:5048-5050.
51. Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S.I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. 1997. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275:1943-1947.
52. Steck, P.A., Pershouse, M.A., Jasser, S.A., Yung, W.K., Lin, H., Ligon, A.H., Langford, L.A., Baumgard, M.L., Hattier, T., Davis, T., et al. 1997. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15:356-362.
53. Wang, S.I., Puc, J., Li, J., Bruce, J.N., Cairns, P., Sidransky, D., and Parsons, R. 1997. Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res 57:4183-4186.
54. Heldin, C.H. 1996. Protein tyrosine kinase receptors. Cancer Surv 27:7-24.
55. Katayam, M., Yoshida, K., Ishimori, H., Katayama, M., Kawase, T., Motoyama, J., and Kamiguchi, H. 2002. Patched and smoothened mRNA expression in human astrocytic tumors inversely correlates with histological malignancy. J Neurooncol 59:107-115.
56. Levanat, S., Gorlin, R.J., Fallet, S., Johnson, D.R., Fantasia, J.E., and Bale, A.E. 1996. A two-hit model for developmental defects in Gorlin syndrome. Nat Genet 12:85-87.
57. Turcot, J., Despres, J.P., and St Pierre, F. 1959. Malignant tumors of the central nervous system associated with familial polyposis of the colon: report of two cases. Dis Colon Rectum 2:465-468.
58. Eberhart, C.G., Kratz, J., Wang, Y., Summers, K., Stearns, D., Cohen, K., Dang, C.V., and Burger, P.C. 2004. Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol 63:441-449.
59. Kenney, A.M., Cole, M.D., and Rowitch, D.H. 2003. Nmyc upregulation by sonic hedgehog signaling promotes proliferation in developing cerebellar granule neuron precursors. Development 130:15-28.
60. Oliver, T.G., Grasfeder, L.L., Carroll, A.L., Kaiser, C., Gillingham, C.L., Lin, S.M., Wickramasinghe, R., Scott, M.P., and Wechsler-Reya, R.J. 2003. Transcriptional profiling of the Sonic hedgehog response: a critical role for N-myc in proliferation of neuronal precursors. Proc Natl Acad Sci U S A 100:7331-7336.
61. Hakin-Smith, V., Jellinek, D.A., Levy, D., Carroll, T., Teo, M., Timperley, W.R., McKay, M.J., Reddel, R.R., and Royds, J.A. 2003. Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. Lancet 361:836-838.
62. Kaur, B., Khwaja, F.W., Severson, E.A., Matheny, S.L., Brat, D.J., and Van Meir, E.G. 2005. Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neurooncol 7:134-153.
63. Feinberg, A.P., and Tycko, B. 2004. The history of cancer epigenetics. Nat Rev Cancer 4:143-153.
64. Richards, E.J. 2006. Inherited epigenetic variation--revisiting soft inheritance. Nat Rev Genet 7:395-401.
65. Merlo, A., Herman, J.G., Mao, L., Lee, D.J., Gabrielson, E., Burger, P.C., Baylin, S.B., and Sidransky, D. 1995. 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1:686-692.
66. Gama-Sosa, M.A., Slagel, V.A., Trewyn, R.W., Oxenhandler, R., Kuo, K.C., Gehrke, C.W., and Ehrlich, M. 1983. The 5-methylcytosine content of DNA from human tumors. Nucleic Acids Res 11:6883-6894.
67. Bruna, A., Darken, R.S., Rojo, F., Ocana, A., Penuelas, S., Arias, A., Paris, R., Tortosa, A., Mora, J., Baselga, J., et al. 2007. High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell 11:147-160.
68. Tuck-Muller, C.M., Narayan, A., Tsien, F., Smeets, D.F., Sawyer, J., Fiala, E.S., Sohn, O.S., and Ehrlich, M. 2000. DNA hypomethylation and unusual chromosome instability in cell lines from ICF syndrome patients. Cytogenet Cell Genet 89:121-128.
69. Lee, R.C., Feinbaum, R.L., and Ambros, V. 1993. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75:843-854.
70. Bartel, D.P. 2004. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281-297.
71. Lim, L.P., Glasner, M.E., Yekta, S., Burge, C.B., and Bartel, D.P. 2003. Vertebrate microRNA genes. Science 299:1540.
72. Bentwich, I., Avniel, A., Karov, Y., Aharonov, R., Gilad, S., Barad, O., Barzilai, A., Einat, P., Einav, U., Meiri, E., et al. 2005. Identification of hundreds of conserved and nonconserved human microRNAs. Nat Genet 37:766-770.
73. Esquela-Kerscher, A., and Slack, F.J. 2006. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 6:259-269.
74. Calin, G.A., and Croce, C.M. 2006. MicroRNA-cancer connection: the beginning of a new tale. Cancer Res 66:7390-7394.
75. Calin, G.A., Sevignani, C., Dumitru, C.D., Hyslop, T., Noch, E., Yendamuri, S., Shimizu, M., Rattan, S., Bullrich, F., Negrini, M., et al. 2004. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 101:2999-3004.
76. Lu, J., Getz, G., Miska, E.A., Alvarez-Saavedra, E., Lamb, J., Peck, D., Sweet-Cordero, A., Ebert, B.L., Mak, R.H., Ferrando, A.A., et al. 2005. MicroRNA expression profiles classify human cancers. Nature 435:834-838.
77. Chan, J.A., Krichevsky, A.M., and Kosik, K.S. 2005. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 65:6029-6033.
78. Cairncross, J.G., Ueki, K., Zlatescu, M.C., Lisle, D.K., Finkelstein, D.M., Hammond, R.R., Silver, J.S., Stark, P.C., Macdonald, D.R., Ino, Y., et al. 1998. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473-1479.
79. Fallon, K.B., Palmer, C.A., Roth, K.A., Nabors, L.B., Wang, W., Carpenter, M., Banerjee, R., Forsyth, P., Rich, K., and Perry, A. 2004. Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas. J Neuropathol Exp Neurol 63:314-322.
80. Schmidt, M.C., Antweiler, S., Urban, N., Mueller, W., Kuklik, A., Meyer-Puttlitz, B., Wiestler, O.D., Louis, D.N., Fimmers, R., and von Deimling, A. 2002. Impact of genotype and morphology on the prognosis of glioblastoma. J Neuropathol Exp Neurol 61:321-328.
81. Nutt, C.L., Mani, D.R., Betensky, R.A., Tamayo, P., Cairncross, J.G., Ladd, C., Pohl, U., Hartmann, C., McLaughlin, M.E., Batchelor, T.T., et al. 2003. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 63:1602-1607.
82. Phillips, H.S., Kharbanda, S., Chen, R., Forrest, W.F., Soriano, R.H., Wu, T.D., Misra, A., Nigro, J.M., Colman, H., Soroceanu, L., et al. 2006. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9:157-173.
83. Gaya, A., Rees, J., Greenstein, A., and Stebbing, J. 2002. The use of temozolomide in recurrent malignant gliomas. Cancer Treat Rev 28:115-120.
84. Hegi, M.E., Diserens, A.C., Godard, S., Dietrich, P.Y., Regli, L., Ostermann, S., Otten, P., Van Melle, G., de Tribolet, N., and Stupp, R. 2004. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 10:1871-1874.
85. Friedman, H.S., McLendon, R.E., Kerby, T., Dugan, M., Bigner, S.H., Henry, A.J., Ashley, D.M., Krischer, J., Lovell, S., Rasheed, K., et al. 1998. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 16:3851-3857.
86. Hegi, M.E., Diserens, A.C., Gorlia, T., Hamou, M.F., de Tribolet, N., Weller, M., Kros, J.M., Hainfellner, J.A., Mason, W., Mariani, L., et al. 2005. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003.
87. Stupp, R., Hegi, M.E., van den Bent, M.J., Mason, W.P., Weller, M., Mirimanoff, R.O., and Cairncross, J.G. 2006. Changing paradigms--an update on the multidisciplinary management of malignant glioma. Oncologist 11:165-180.
88. Butowski, N.A., Sneed, P.K., and Chang, S.M. 2006. Diagnosis and treatment of recurrent highgrade astrocytoma. J Clin Oncol 24:1273-1280.
89. Wong, E.T., Hess, K.R., Gleason, M.J., Jaeckle, K.A., Kyritsis, A.P., Prados, M.D., Levin, V.A., and Yung, W.K. 1999. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17:2572-2578.
90. Sathornsumetee, S., Reardon, D.A., Desjardins, A., Quinn, J.A., Vredenburgh, J.J., and Rich, J.N. 2007. Molecularly targeted therapy for malignant glioma. Cancer 110:13-24.
91. Brandsma, D., and van den Bent, M.J. 2007. Molecular targeted therapies and chemotherapy in malignant gliomas. Curr Opin Oncol 19:598-605.
92. Wen, P.Y., Yung, W.K., Lamborn, K.R., Dahia, P.L., Wang, Y., Peng, B., Abrey, L.E., Raizer, J., Cloughesy, T.F., Fink, K., et al. 2006. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res 12:4899-4907.
93. Dresemann, G. 2005. Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. Ann Oncol 16:1702-1708.
94. Reardon, D.A., Egorin, M.J., Quinn, J.A., Rich, J.N., Gururangan, S., Vredenburgh, J.J., Desjardins, A., Sathornsumetee, S., Provenzale, J.M., Herndon, J.E., 2nd, et al. 2005. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol 23:9359-9368.
95. Desjardins, A., Quinn, J.A., Vredenburgh, J.J., Sathornsumetee, S., Friedman, A.H., Herndon, J.E., McLendon, R.E., Provenzale, J.M., Rich, J.N., Sampson, J.H., et al. 2007. Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. J Neurooncol 83:53-60.
96. Pietras, K., Ostman, A., Sjoquist, M., Buchdunger, E., Reed, R.K., Heldin, C.H., and Rubin, K. 2001. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 61:2929-2934.
97. Rich, J.N., Reardon, D.A., Peery, T., Dowell, J.M., Quinn, J.A., Penne, K.L., Wikstrand, C.J., Van Duyn, L.B., Dancey, J.E., McLendon, R.E., et al. 2004. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22:133-142.
98. Mellinghoff, I.K., Wang, M.Y., Vivanco, I., Haas-Kogan, D.A., Zhu, S., Dia, E.Q., Lu, K.V., Yoshimoto, K., Huang, J.H., Chute, D.J., et al. 2005. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353:2012-2024.
99. Vredenburgh, J.J., Desjardins, A., Herndon, J.E., 2nd, Dowell, J.M., Reardon, D.A., Quinn, J.A., Rich, J.N., Sathornsumetee, S., Gururangan, S., Wagner, M., et al. 2007. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13:1253-1259.
100. Vredenburgh, J.J., Desjardins, A., Herndon, J.E., 2nd, Marcello, J., Reardon, D.A., Quinn, J.A., Rich, J.N., Sathornsumetee, S., Gururangan, S., Sampson, J., et al. 2007. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722-4729.
101. Batchelor, T.T., Sorensen, A.G., di Tomaso, E., Zhang, W.T., Duda, D.G., Cohen, K.S., Kozak, K.R., Cahill, D.P., Chen, P.J., Zhu, M., et al. 2007. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83-95.
102. Stern, J.I., and Raizer, J.J. 2006. Chemotherapy in the treatment of malignant gliomas. Expert Rev Anticancer Ther 6:755-767.
103. Reardon, D.A., Rich, J.N., Friedman, H.S., and Bigner, D.D. 2006. Recent advances in the treatment of malignant astrocytoma. J Clin Oncol 24:1253-1265.
104. Romer, J.T., Kimura, H., Magdaleno, S., Sasai, K., Fuller, C., Baines, H., Connelly, M., Stewart, C.F., Gould, S., Rubin, L.L., et al. 2004. Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/-)p53(-/-) mice. Cancer Cell 6:229-240.
105. Cutter, J.L., Kurozumi, K., Chiocca, E.A., and Kaur, B. 2006. Gene therapeutics: the future of brain tumor therapy? Expert Rev Anticancer Ther 6:1053-1064.
106. Morgan, R.A., Dudley, M.E., Wunderlich, J.R., Hughes, M.S., Yang, J.C., Sherry, R.M., Royal, R.E., Topalian, S.L., Kammula, U.S., Restifo, N.P., et al. 2006. Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes. Science.
107. Hatten, M.E. 1990. Riding the glial monorail: a common mechanism for glial-guided neuronal migration in different regions of the developing mammalian brain. Trends Neurosci 13:179-184.
108. Mayer-Proschel, M., Kalyani, A.J., Mujtaba, T., and Rao, M.S. 1997. Isolation of lineage-restricted neuronal precursors from multipotent neuroepithelial stem cells. Neuron 19:773-785.
109. Takebayashi, H., Nabeshima, Y., Yoshida, S., Chisaka, O., and Ikenaka, K. 2002. The basic helix-loop-helix factor olig2 is essential for the development of motoneuron and oligodendrocyte lineages. Curr Biol 12:1157-1163.
110. Lu, Q.R., Sun, T., Zhu, Z., Ma, N., Garcia, M., Stiles, C.D., and Rowitch, D.H. 2002. Common developmental requirement for Olig function indicates a motor neuron/oligodendrocyte connection. Cell 109:75-86.
111. Zhou, Q., and Anderson, D.J. 2002. The bHLH transcription factors OLIG2 and OLIG1 couple neuronal and glial subtype specification. Cell 109:61-73.
112. Noble, M., and Dietrich, J. 2004. The complex identity of brain tumors: emerging concerns regarding origin, diversity and plasticity. Trends Neurosci 27:148-154.
113. Hunter, K.E., and Hatten, M.E. 1995. Radial glial cell transformation to astrocytes is bidirectional: regulation by a diffusible factor in embryonic forebrain. Proc Natl Acad Sci U S A 92:2061-2065.
114. Soriano, E., Alvarado-Mallart, R.M., Dumesnil, N., Del Rio, J.A., and Sotelo, C. 1997. Cajal-Retzius cells regulate the radial glia phenotype in the adult and developing cerebellum and alter granule cell migration. Neuron 18:563-577.
115. Schmid, R.S., McGrath, B., Berechid, B.E., Boyles, B., Marchionni, M., Sestan, N., and Anton, E.S. 2003. Neuregulin 1-erbB2 signaling is required for the establishment of radial glia and their transformation into astrocytes in cerebral cortex. Proc Natl Acad Sci U S A 100:4251-4256.
116. Kimelberg, H.K. 2004. The problem of astrocyte identity. Neurochem Int 45:191-202.
117. Levison, S.W., and Goldman, J.E. 1993. Both oligodendrocytes and astrocytes develop from progenitors in the subventricular zone of postnatal rat forebrain. Neuron 10:201-212.
118. Doetsch, F., Caille, I., Lim, D.A., Garcia-Verdugo, J.M., and Alvarez-Buylla, A. 1999. Subventricular zone astrocytes are neural stem cells in the adult mammalian brain. Cell 97:703-716.
119. Eriksson, P.S., Perfilieva, E., Bjork-Eriksson, T., Alborn, A.M., Nordborg, C., Peterson, D.A., and Gage, F.H. 1998. Neurogenesis in the adult human hippocampus. Nat Med 4:1313-1317.
120. Nunes, M.C., Roy, N.S., Keyoung, H.M., Goodman, R.R., McKhann, G., 2nd, Jiang, L., Kang, J., Nedergaard, M., and Goldman, S.A. 2003. Identification and isolation of multipotential neural progenitor cells from the subcortical white matter of the adult human brain. Nat Med 9:439-447.
121. Ming, G.L., and Song, H. 2005. Adult neurogenesis in the mammalian central nervous system. Annu Rev Neurosci 28:223-250.
122. Rowitch, D.H. 2004. Glial specification in the vertebrate neural tube. Nat Rev Neurosci 5:409-419.
123. Menn, B., Garcia-Verdugo, J.M., Yaschine, C., Gonzalez-Perez, O., Rowitch, D., and Alvarez-Buylla, A. 2006. Origin of oligodendrocytes in the subventricular zone of the adult brain. J Neurosci 26:7907-7918.
124. Hall, A., Giese, N.A., and Richardson, W.D. 1996. Spinal cord oligodendrocytes develop from ventrally derived progenitor cells that express PDGF alpha-receptors. Development 122:4085-4094.
125. Dawson, M.R., Levine, J.M., and Reynolds, R. 2000. NG2-expressing cells in the central nervous system: are they oligodendroglial progenitors? J Neurosci Res 61:471-479.
126. Palmer, T.D., Takahashi, J., and Gage, F.H. 1997. The adult rat hippocampus contains primordial neural stem cells. Mol Cell Neurosci 8:389-404.
127. Kraus, J.A., Koopmann, J., Kaskel, P., Maintz, D., Brandner, S., Schramm, J., Louis, D.N., Wiestler, O.D., and von Deimling, A. 1995. Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol 54:91-95.
128. Ignatova, T.N., Kukekov, V.G., Laywell, E.D., Suslov, O.N., Vrionis, F.D., and Steindler, D.A. 2002. Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia 39:193-206.
129. Singh, S.K., Clarke, I.D., Terasaki, M., Bonn, V.E., Hawkins, C., Squire, J., and Dirks, P.B. 2003. Identification of a cancer stem cell in human brain tumors. Cancer Res 63:5821-5828.
130. Hemmati, H.D., Nakano, I., Lazareff, J.A., Masterman-Smith, M., Geschwind, D.H., Bronner-Fraser, M., and Kornblum, H.I. 2003. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci U S A 100:15178-15183.
131. Singh, S.K., Hawkins, C., Clarke, I.D., Squire, J.A., Bayani, J., Hide, T., Henkelman, R.M., Cusimano, M.D., and Dirks, P.B. 2004. Identification of human brain tumour initiating cells. Nature 432:396-401.
132. Taylor, M.D., Poppleton, H., Fuller, C., Su, X., Liu, Y., Jensen, P., Magdaleno, S., Dalton, J., Calabrese, C., Board, J., et al. 2005. Radial glia cells are candidate stem cells of ependymoma. Cancer Cell 8:323-335.
133. Johansson, C.B., Momma, S., Clarke, D.L., Risling, M., Lendahl, U., and Frisen, J. 1999. Identification of a neural stem cell in the adult mammalian central nervous system. Cell 96:25-34.
134. Gould, E., Tanapat, P., McEwen, B.S., Flugge, G., and Fuchs, E. 1998. Proliferation of granule cell precursors in the dentate gyrus of adult monkeys is diminished by stress. Proc Natl Acad Sci U S A 95:3168-3171.
135. Levison, S.W., Young, G.M., and Goldman, J.E. 1999. Cycling cells in the adult rat neocortex preferentially generate oligodendroglia. J Neurosci Res 57:435-446.
136. Pringle, N.P., Mudhar, H.S., Collarini, E.J., and Richardson, W.D. 1992. PDGF receptors in the rat CNS: during late neurogenesis, PDGF alpha-receptor expression appears to be restricted to glial cells of the oligodendrocyte lineage. Development 115:535-551.
137. Raff, M.C., Miller, R.H., and Noble, M. 1983. A glial progenitor cell that develops in vitro into an astrocyte or an oligodendrocyte depending on culture medium. Nature 303:390-396.
138. Wolswijk, G., and Noble, M. 1989. Identification of an adult-specific glial progenitor cell. Development 105:387-400.
139. Bogler, O., Wren, D., Barnett, S.C., Land, H., and Noble, M. 1990. Cooperation between two growth factors promotes extended self-renewal and inhibits differentiation of oligodendrocytetype-2 astrocyte (O-2A) progenitor cells. Proc Natl Acad Sci U S A 87:6368-6372.
140. Assanah, M., Lochhead, R., Ogden, A., Bruce, J., Goldman, J., and Canoll, P. 2006. Glial progenitors in adult white matter are driven to form malignant gliomas by platelet-derived growth factor-expressing retroviruses. J Neurosci 26:6781-6790.
141. Goldman, J.E. 2000. Glial differentiation and lineages. J Neurosci Res 59:410-412.
142. Chekenya, M., and Pilkington, G.J. 2002. NG2 precursor cells in neoplasia: functional, histogenesis and therapeutic implications for malignant brain tumours. J Neurocytol 31:507-521.
143. Ligon, K.L., Huillard, E., Mehta, S., Kesari, S., Liu, H., Alberta, J.A., Bachoo, R.M., Kane, M., Louis, D.N., Depinho, R.A., et al. 2007. Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma. Neuron 53:503-517.
144. Bachoo, R.M., Maher, E.A., Ligon, K.L., Sharpless, N.E., Chan, S.S., You, M.J., Tang, Y., De-Frances, J., Stover, E., Weissleder, R., et al. 2002. Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell 1:269-277.
145. Bruggeman, S.W., Hulsman, D., Tanger, E., Buckle, T., Blom, M., Zevenhoven, J., van Tellingen, O., and van Lohuizen, M. 2007. Bmi1 controls tumor development in an Ink4a/Arf-independent manner in a mouse model for glioma. Cancer Cell 12:328-341.
146. Piccirillo, S.G., Reynolds, B.A., Zanetti, N., Lamorte, G., Binda, E., Broggi, G., Brem, H., Olivi, A., Dimeco, F., and Vescovi, A.L. 2006. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 444:761-765.
147. Katsetos, C.D., Del Valle, L., Legido, A., de Chadarevian, J.P., Perentes, E., and Mork, S.J. 2003. On the neuronal/neuroblastic nature of medulloblastomas: a tribute to Pio del Rio Hortega and Moises Polak. Acta Neuropathol (Berl) 105:1-13.
148. Pomeroy, S.L., Tamayo, P., Gaasenbeek, M., Sturla, L.M., Angelo, M., McLaughlin, M.E., Kim, J.Y., Goumnerova, L.C., Black, P.M., Lau, C., et al. 2002. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415:436-442.
149. Read, T.A., Hegedus, B., Wechsler-Reya, R., and Gutmann, D.H. 2006. The neurobiology of neurooncology. Ann Neurol 60:3-11.
150. Goldman, S. 2003. Glia as neural progenitor cells. Trends Neurosci 26:590-596.
151. Kondo, T., and Raff, M. 2004. Chromatin remodeling and histone modification in the conversion of oligodendrocyte precursors to neural stem cells. Genes Dev 18:2963-2972.
152. Takahashi, K., and Yamanaka, S. 2006. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:663-676.
153. Nicolis, S.K. 2007. Cancer stem cells and "stemness" genes in neuro-oncology. Neurobiol Dis 25:217-229.
154. Coffin, J., Hughes, S., and Varmus, H.E. 1997. Retroviruses: Cold Spring Harbor Laboratory Press, Plainview (NY).
155. Burmeister, T. 2001. Oncogenic retroviruses in animals and humans. Rev Med Virol 11:369-380.
156. Temin, H.M., and Mizutani, S. 1970. RNA-dependent DNA polymerase in virions of Rous sarcoma virus. Nature 226:1211-1213.
157. Baltimore, D. 1970. RNA-dependent DNA polymerase in virions of RNA tumour viruses. Nature 226:1209-1211.
158. van Lohuizen, M., and Berns, A. 1990. Tumorigenesis by slow-transforming retroviruses - an update. Biochim Biophys Acta 1032:213-235.
159. Jonkers, J., and Berns, A. 1996. Retroviral insertional mutagenesis as a strategy to identify cancer genes. Biochim Biophys Acta 1287:29-57.
160. Qian, Z., Wang, H., Empig, C., Anderson, W.F., and Albritton, L.M. 2004. Complementation of a binding-defective retrovirus by a host cell receptor mutant. J Virol 78:5766-5772.
161. Uhrbom, L., and Holland, E.C. 2004. Somatic cell gene transfer. In Mouse Models of Human Cancer. New York: John Wiley & Sons, Inc.
162. Lewis, P.F., and Emerman, M. 1994. Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. J Virol 68:510-516.
163. Hayward, W.S., Neel, B.G., and Astrin, S.M. 1981. Activation of a cellular onc gene by promoter insertion in ALV-induced lymphoid leukosis. Nature 290:475-480.
164. Schroder, A.R., Shinn, P., Chen, H., Berry, C., Ecker, J.R., and Bushman, F. 2002. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110:521-529.
165. Wu, X., Li, Y., Crise, B., and Burgess, S.M. 2003. Transcription start regions in the human genome are favored targets for MLV integration. Science 300:1749-1751.
166. Wu, X., Luke, B.T., and Burgess, S.M. 2006. Redefining the common insertion site. Virology 344:292-295.
167. de Ridder, J., Uren, A., Kool, J., Reinders, M., and Wessels, L. 2006. Detecting statistically significant common insertion sites in retroviral insertional mutagenesis screens. PLoS Comput Biol 2:e166.
168. de Ridder, J., Kool, J., Uren, A., Bot, J., Wessels, L., and Reinders, M. 2007. Co-occurrence analysis of insertional mutagenesis data reveals cooperating oncogenes. Bioinformatics 23:i133-141.
169. Lund, A.H., Turner, G., Trubetskoy, A., Verhoeven, E., Wientjens, E., Hulsman, D., Russell, R., DePinho, R.A., Lenz, J., and van Lohuizen, M. 2002. Genome-wide retroviral insertional tagging of genes involved in cancer in Cdkn2a-deficient mice. Nat Genet 32:160-165.
170. Mikkers, H., Allen, J., Knipscheer, P., Romeijn, L., Hart, A., Vink, E., Berns, A., and Romeyn, L. 2002. High-throughput retroviral tagging to identify components of specific signaling pathways in cancer. Nat Genet 32:153-159.
171. Suzuki, T., Shen, H., Akagi, K., Morse, H.C., Malley, J.D., Naiman, D.Q., Jenkins, N.A., and Copeland, N.G. 2002. New genes involved in cancer identified by retroviral tagging. Nat Genet 32:166-174.
172. Wentzensen, N., Vinokurova, S., and von Knebel Doeberitz, M. 2004. Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract. Cancer Res 64:3878-3884.
173. Paterlini-Brechot, P., Saigo, K., Murakami, Y., Chami, M., Gozuacik, D., Mugnier, C., Lagorce, D., and Brechot, C. 2003. Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene. Oncogene 22:3911-3916.
174. Johansson, F.K., Brodd, J., Eklof, C., Ferletta, M., Hesselager, G., Tiger, C.F., Uhrbom, L., and Westermark, B. 2004. Identification of candidate cancer-causing genes in mouse brain tumors by retroviral tagging. Proc Natl Acad Sci U S A.
175. Theodorou, V., Kimm, M.A., Boer, M., Wessels, L., Theelen, W., Jonkers, J., and Hilkens, J. 2007. MMTV insertional mutagenesis identifies genes, gene families and pathways involved in mammary cancer. Nat Genet 39:759-769.
176. Collier, L.S., Carlson, C.M., Ravimohan, S., Dupuy, A.J., and Largaespada, D.A. 2005. Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse. Nature 436:272-276.
177. Dupuy, A.J., Akagi, K., Largaespada, D.A., Copeland, N.G., and Jenkins, N.A. 2005. Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system. Nature 436:221-226.
178. Collier, L.S., and Largaespada, D.A. 2006. Transforming science: cancer gene identification. Curr Opin Genet Dev 16:23-29.
179. Akagi, K., Suzuki, T., Stephens, R.M., Jenkins, N.A., and Copeland, N.G. 2004. RTCGD: retroviral tagged cancer gene database. Nucleic Acids Res 32:D523-527.
180. Holliday, R. 1996. Neoplastic transformation: the contrasting stability of human and mouse cells. Cancer Surv 28:103-115.
181. Ames, B.N., Shigenaga, M.K., and Hagen, T.M. 1993. Oxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci U S A 90:7915-7922.
182. Rodriguez-Viciana, P., Warne, P.H., Khwaja, A., Marte, B.M., Pappin, D., Das, P., Waterfield, M.D., Ridley, A., and Downward, J. 1997. Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 89:457-467.
183. Hahn, W.C., Counter, C.M., Lundberg, A.S., Beijersbergen, R.L., Brooks, M.W., and Weinberg, R.A. 1999. Creation of human tumour cells with defined genetic elements. Nature 400:464-468.
184. Wright, W.E., and Shay, J.W. 2000. Telomere dynamics in cancer progression and prevention: fundamental differences in human and mouse telomere biology. Nat Med 6:849-851.
185. Rangarajan, A., and Weinberg, R.A. 2003. Opinion: Comparative biology of mouse versus human cells: modelling human cancer in mice. Nat Rev Cancer 3:952-959.
186. Jonkers, J., and Berns, A. 2002. Conditional mouse models of sporadic cancer. Nat Rev Cancer 2:251-265.
187. Ding, H., Roncari, L., Shannon, P., Wu, X., Lau, N., Karaskova, J., Gutmann, D.H., Squire, J.A., Nagy, A., and Guha, A. 2001. Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas. Cancer Res 61:3826-3836.
188. Reilly, K.M., Loisel, D.A., Bronson, R.T., McLaughlin, M.E., and Jacks, T. 2000. Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nat Genet 26:109-113.
189. Weissenberger, J., Steinbach, J.P., Malin, G., Spada, S., Rulicke, T., and Aguzzi, A. 1997. Development and malignant progression of astrocytomas in GFAP-v-src transgenic mice. Oncogene 14:2005-2013.
190. Kamijo, T., Bodner, S., van de Kamp, E., Randle, D.H., and Sherr, C.J. 1999. Tumor spectrum in ARF-deficient mice. Cancer Res 59:2217-2222.
191. Dai, C., Celestino, J.C., Okada, Y., Louis, D.N., Fuller, G.N., and Holland, E.C. 2001. PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev 15:1913-1925.
192. Weiss, W.A., Burns, M.J., Hackett, C., Aldape, K., Hill, J.R., Kuriyama, H., Kuriyama, N., Milshteyn, N., Roberts, T., Wendland, M.F., et al. 2003. Genetic determinants of malignancy in a mouse model for oligodendroglioma. Cancer Res 63:1589-1595.
193. Ding, H., Shannon, P., Lau, N., Wu, X., Roncari, L., Baldwin, R.L., Takebayashi, H., Nagy, A., Gutmann, D.H., and Guha, A. 2003. Oligodendrogliomas result from the expression of an activated mutant epidermal growth factor receptor in a RAS transgenic mouse astrocytoma model. Cancer Res 63:1106-1113.
194. Wei, Q., Clarke, L., Scheidenhelm, D.K., Qian, B., Tong, A., Sabha, N., Karim, Z., Bock, N.A., Reti, R., Swoboda, R., et al. 2006. High-grade glioma formation results from postnatal pten loss or mutant epidermal growth factor receptor expression in a transgenic mouse glioma model. Cancer Res 66:7429-7437.
195. Xiao, A., Wu, H., Pandolfi, P.P., Louis, D.N., and Van Dyke, T. 2002. Astrocyte inactivation of the pRb pathway predisposes mice to malignant astrocytoma development that is accelerated by PTEN mutation. Cancer Cell 1:157-168.
196. Holland, E.C., Li, Y., Celestino, J., Dai, C., Schaefer, L., Sawaya, R.A., and Fuller, G.N. 2000. Astrocytes give rise to oligodendrogliomas and astrocytomas after gene transfer of polyoma virus middle T antigen in vivo. Am J Pathol 157:1031-1037.
197. Holland, E.C., Celestino, J., Dai, C., Schaefer, L., Sawaya, R.E., and Fuller, G.N. 2000. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet 25:55-57.
198. Uhrbom, L., Hesselager, G., Nister, M., and Westermark, B. 1998. Induction of brain tumors in mice using a recombinant platelet-derived growth factor B-chain retrovirus. Cancer Res 58:5275-5279.
199. Zhu, Y., Guignard, F., Zhao, D., Liu, L., Burns, D.K., Mason, R.P., Messing, A., and Parada, L.F. 2005. Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell 8:119-130.
200. Uhrbom, L., Kastemar, M., Johansson, F.K., Westermark, B., and Holland, E.C. 2005. Cell type-specific tumor suppression by Ink4a and Arf in Kras-induced mouse gliomagenesis. Cancer Res 65:2065-2069.
201. Uhrbom, L., Dai, C., Celestino, J.C., Rosenblum, M.K., Fuller, G.N., and Holland, E.C. 2002. Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt. Cancer Res 62:5551-5558.
202. Charest, A., Wilker, E.W., McLaughlin, M.E., Lane, K., Gowda, R., Coven, S., McMahon, K., Kovach, S., Feng, Y., Yaffe, M.B., et al. 2006. ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/ phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice. Cancer Res 66:7473-7481.
203. Fisher, G.H., Orsulic, S., Holland, E., Hively, W.P., Li, Y., Lewis, B.C., Williams, B.O., and Varmus, H.E. 1999. Development of a flexible and specific gene delivery system for production of murine tumor models. Oncogene 18:5253-5260.
204. Hesselager, G., Uhrbom, L., Westermark, B., and Nister, M. 2003. Complementary effects of platelet-derived growth factor autocrine stimulation and p53 or Ink4a-Arf deletion in a mouse glioma model. Cancer Res 63:4305-4309.
205. Shih, A.H., Dai, C., Hu, X., Rosenblum, M.K., Koutcher, J.A., and Holland, E.C. 2004. Dose-dependent effects of platelet-derived growth factor-B on glial tumorigenesis. Cancer Res 64:4783-4789.
206. Uhrbom, L., Nerio, E., and Holland, E.C. 2004. Dissecting tumor maintenance requirements using bioluminescence imaging of cell proliferation in a mouse glioma model. Nat Med 10:1257-1260.
207. Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M.P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C.S., Pawliuk, R., Morillon, E., et al. 2003. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302:415-419.
208. Dave, U.P., Jenkins, N.A., and Copeland, N.G. 2004. Gene therapy insertional mutagenesis insights. Science 303:333.
209. Johansson, F.K., Goransson, H., and Westermark, B. 2005. Expression analysis of genes involved in brain tumor progression driven by retroviral insertional mutagenesis in mice. Oncogene 24:3896-3905.
210. Forsberg-Nilsson, K., Erlandsson, A., Zhang, X.Q., Ueda, H., Svensson, K., Nister, M., Trapp, B.D., Peterson, A.C., and Westermark, B. 2003. Oligodendrocyte precursor hypercellularity and abnormal retina development in mice overexpressing PDGF-B in myelinating tracts. Glia 41:276-289.
211. Demoulin, J.B., Enarsson, M., Larsson, J., Essaghir, A., Heldin, C.H., and Forsberg-Nilsson, K. 2006. The gene expression profile of PDGF-treated neural stem cells corresponds to partially differentiated neurons and glia. Growth Factors 24:184-196.
212. Clement, V., Sanchez, P., de Tribolet, N., Radovanovic, I., and Ruiz i Altaba, A. 2007. HEDGE-HOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol 17:165-172.
213. Meletis, K., Wirta, V., Hede, S.M., Nister, M., Lundeberg, J., and Frisen, J. 2006. p53 suppresses the self-renewal of adult neural stem cells. Development 133:363-369.
214. Jepsen, K., Solum, D., Zhou, T., McEvilly, R.J., Kim, H.J., Glass, C.K., Hermanson, O., and Rosenfeld, M.G. 2007. SMRT-mediated repression of an H3K27 demethylase in progression from neural stem cell to neuron. Nature.
215. Wolf, R.M., Draghi, N., Liang, X., Dai, C., Uhrbom, L., Eklof, C., Westermark, B., Holland, E.C., and Resh, M.D. 2003. p190RhoGAP can act to inhibit PDGF-induced gliomas in mice: a putative tumor suppressor encoded on human chromosome 19q13.3. Genes Dev 17:476-487.
216. Ferletta, M., Uhrbom, L., Olofsson, T., Ponten, F., and Westermark, B. 2007. Sox10 has a broad expression pattern in gliomas and enhances platelet-derived growth factor-B--induced gliomagenesis. Mol Cancer Res 5:891-897.
217. Lazo, P.A., and Tsichlis, P.N. 1990. Biology and pathogenesis of retroviruses. Semin Oncol 17:269-294.
218. Sonoda, Y., Ozawa, T., Hirose, Y., Aldape, K.D., McMahon, M., Berger, M.S., and Pieper, R.O. 2001. Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma. Cancer Res 61:4956-4960.
219. Slape, C., Hartung, H., Lin, Y.W., Bies, J., Wolff, L., and Aplan, P.D. 2007. Retroviral insertional mutagenesis identifies genes that collaborate with NUP98-HOXD13 during leukemic transformation. Cancer Res 67:5148-5155.
220. Huppi, K., Volfovsky, N., Mackiewicz, M., Runfola, T., Jones, T.L., Martin, S.E., Stephens, R., and Caplen, N.J. 2007. MicroRNAs and genomic instability. Semin Cancer Biol 17:65-73.
221. Bester, A.C., Schwartz, M., Schmidt, M., Garrigue, A., Hacein-Bey-Abina, S., Cavazzana-Calvo, M., Ben-Porat, N., Von Kalle, C., Fischer, A., and Kerem, B. 2006. Fragile sites are preferential targets for integrations of MLV vectors in gene therapy. Gene Ther 13:1057-1059.
222. Richards, R.I. 2001. Fragile and unstable chromosomes in cancer: causes and consequences. Trends Genet 17:339-345.
223. Ching, Y.P., Chan, S.F., Jeang, K.T., and Jin, D.Y. 2006. The retroviral oncoprotein Tax targets the coiled-coil centrosomal protein TAX1BP2 to induce centrosome overduplication. Nat Cell Biol 8:717-724.
224. Morimoto-Tomita, M., Uchimura, K., Bistrup, A., Lum, D.H., Egeblad, M., Boudreau, N., Werb, Z., and Rosen, S.D. 2005. Sulf-2, a proangiogenic heparan sulfate endosulfatase, is upregulated in breast cancer. Neoplasia 7:1001-1010.
225. Dai, Y., Yang, Y., MacLeod, V., Yue, X., Rapraeger, A.C., Shriver, Z., Venkataraman, G., Sasisekharan, R., and Sanderson, R.D. 2005. HSulf-1 and HSulf-2 are potent inhibitors of myeloma tumor growth in vivo. J Biol Chem 280:40066-40073.
226. Zhang, L., Chenwei, L., Mahmood, R., van Golen, K., Greenson, J., Li, G., D'Silva, N.J., Li, X., Burant, C.F., Logsdon, C.D., et al. 2006. Identification of a putative tumor suppressor gene Rap1GAP in pancreatic cancer. Cancer Res 66:898-906.
227. Zhang, Z., Mitra, R.S., Henson, B.S., Datta, N.S., McCauley, L.K., Kumar, P., Lee, J.S., Carey, T.E., and D'Silva, N.J. 2006. Rap1GAP inhibits tumor growth in oropharyngeal squamous cell carcinoma. Am J Pathol 168:585-596.
228. Tsygankova, O.M., Prendergast, G.V., Puttaswamy, K., Wang, Y., Feldman, M.D., Wang, H., Brose, M.S., and Meinkoth, J.L. 2007. Downregulation of Rap1GAP contributes to Ras transformation. Mol Cell Biol 27:6647-6658.
229. Boiko, A.D., Porteous, S., Razorenova, O.V., Krivokrysenko, V.I., Williams, B.R., and Gudkov, A.V. 2006. A systematic search for downstream mediators of tumor suppressor function of p53 reveals a major role of BTG2 in suppression of Ras-induced transformation. Genes Dev 20:236-252.
230. Shou, Y., Ma, Z., Lu, T., and Sorrentino, B.P. 2006. Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy. Proc Natl Acad Sci U S A 103:11730-11735.
231. Sturla, L.M., Cowan, C.W., Guenther, L., Castellino, R.C., Kim, J.Y., and Pomeroy, S.L. 2005. A novel role for extracellular signal-regulated kinase 5 and myocyte enhancer factor 2 in medulloblastoma cell death. Cancer Res 65:5683-5689.
232. Colin, C., Baeza, N., Bartoli, C., Fina, F., Eudes, N., Nanni, I., Martin, P.M., Ouafik, L., and Figarella-Branger, D. 2006. Identification of genes differentially expressed in glioblastoma versus pilocytic astrocytoma using Suppression Subtractive Hybridization. Oncogene 25:2818-2826.
233. Kordes, U., and Hagel, C. 2006. Expression of SOX9 and SOX10 in central neuroepithelial tumor. J Neurooncol 80:151-155.
234. Bannykh, S.I., Stolt, C.C., Kim, J., Perry, A., and Wegner, M. 2006. Oligodendroglial-specific transcriptional factor SOX10 is ubiquitously expressed in human gliomas. J Neurooncol 76:115-127.
235. Watanabe, A., Mabuchi, T., Satoh, E., Furuya, K., Zhang, L., Maeda, S., and Naganuma, H. 2006. Expression of syndecans, a heparan sulfate proteoglycan, in malignant gliomas: participation of nuclear factor-kappaB in upregulation of syndecan-1 expression. J Neurooncol 77:25-32.
236. Ram, R., Lorente, G., Nikolich, K., Urfer, R., Foehr, E., and Nagavarapu, U. 2006. Discoidin domain receptor-1a (DDR1a) promotes glioma cell invasion and adhesion in association with matrix metalloproteinase-2. J Neurooncol 76:239-248.
237. Yamanaka, R., Arao, T., Yajima, N., Tsuchiya, N., Homma, J., Tanaka, R., Sano, M., Oide, A., Sekijima, M., and Nishio, K. 2006. Identification of expressed genes characterizing long-term survival in malignant glioma patients. Oncogene 25:5994-6002.
238. Chekenya, M., Hjelstuen, M., Enger, P.O., Thorsen, F., Jacob, A.L., Probst, B., Haraldseth, O., Pilkington, G., Butt, A., Levine, J.M., et al. 2002. NG2 proteoglycan promotes angiogenesis-dependent tumor growth in CNS by sequestering angiostatin. Faseb J 16:586-588.
239. Miething, C., Grundler, R., Mugler, C., Brero, S., Hoepfl, J., Geigl, J., Speicher, M.R., Ottmann, O., Peschel, C., and Duyster, J. 2007. Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatment. Proc Natl Acad Sci U S A 104:4594-4599.
240. Sjoblom, T., Jones, S., Wood, L.D., Parsons, D.W., Lin, J., Barber, T.D., Mandelker, D., Leary, R.J., Ptak, J., Silliman, N., et al. 2006. The consensus coding sequences of human breast and colorectal cancers. Science 314:268-274.